- Home
- ASTI vs ZVSA Comparison
ASTI vs ZVSA Comparison
Compare ASTI & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTI
- ZVSA
- Stock Information
- Founded
- ASTI 2005
- ZVSA 2014
- Country
- ASTI United States
- ZVSA United States
- Employees
- ASTI N/A
- ZVSA N/A
- Industry
- ASTI Semiconductors
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- ASTI Technology
- ZVSA Health Care
- Exchange
- ASTI Nasdaq
- ZVSA Nasdaq
- Market Cap
- ASTI 3.1M
- ZVSA 3.5M
- IPO Year
- ASTI N/A
- ZVSA N/A
- Fundamental
- Price
- ASTI $1.23
- ZVSA $0.60
- Analyst Decision
- ASTI
- ZVSA Strong Buy
- Analyst Count
- ASTI 0
- ZVSA 1
- Target Price
- ASTI N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- ASTI 133.2K
- ZVSA 117.9K
- Earning Date
- ASTI 05-08-2025
- ZVSA 05-14-2025
- Dividend Yield
- ASTI N/A
- ZVSA N/A
- EPS Growth
- ASTI N/A
- ZVSA N/A
- EPS
- ASTI N/A
- ZVSA N/A
- Revenue
- ASTI $41,893.00
- ZVSA N/A
- Revenue This Year
- ASTI N/A
- ZVSA N/A
- Revenue Next Year
- ASTI N/A
- ZVSA N/A
- P/E Ratio
- ASTI N/A
- ZVSA N/A
- Revenue Growth
- ASTI N/A
- ZVSA N/A
- 52 Week Low
- ASTI $1.20
- ZVSA $0.58
- 52 Week High
- ASTI $35.80
- ZVSA $8.05
- Technical
- Relative Strength Index (RSI)
- ASTI 28.15
- ZVSA 34.12
- Support Level
- ASTI $1.20
- ZVSA $0.69
- Resistance Level
- ASTI $1.41
- ZVSA $0.65
- Average True Range (ATR)
- ASTI 0.14
- ZVSA 0.06
- MACD
- ASTI -0.04
- ZVSA 0.00
- Stochastic Oscillator
- ASTI 5.33
- ZVSA 28.57
About ASTI Ascent Solar Technologies Inc.
Ascent Solar Technologies Inc is engaged in the manufacturing and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.